Signalling pathways involved in clinical responses to chemotherapy

Clinical and Translational Oncology

Volumn 9, Issue 10, 2007, Pages 625-633

  Perona, R ^a   Sanchez Perez I ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Apoptosis; Chemotherapy; Drug resistance; Oncogenes; Radio therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOLIC ACID ANTAGONIST; GEFITINIB; GYRASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MIXED LINEAGE KINASE 3; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE INHIBITOR; TRANSCRIPTION FACTOR REL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR RELB;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CELLULAR STRESS SIGNAL; CHEMOSENSITIVITY; CHROMOSOME 10P; CYTOGENETICS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; DRUG RESPONSE; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; NONHUMAN; OVARY CANCER; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR CELL; UBIQUITINATION; DRUG ANTAGONISM; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELB;

EID: 38449088673     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0115-3     Document Type: Article

References (52)

1. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23-28
2. Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432:338-341
3. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J. Pathol 205:275-292
4. Rickardson L, Fryknas M, Dhar S et al (2005) Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 93:483-492
5. Zhou BB, Elledge SJ (2000) The DNA damage response: Putting checkpoints in perspective. Nature 408:433-439
6. Kruh GD (2003) Introduction to resistance to anticancer agents. Oncogene 22:7262-7264
7. Viatour P, Merville MP, Bours V, Chariot A (2005) Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 30:43-52
8. Staal SP (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 84:5034-5037
9. Jones PF, Jakubowicz T, Pitossi FJ et al (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 88:4171-4175
10. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355
11. Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U SA 98:10983-10985
12. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94:29-86
13. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117-123
14. Liang K, Jin W, Knuefermann C et al (2003) Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353-360
15. Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
16. Hu L, Hofmann J, Lu Y et al (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092
17. Mansouri A, Zhang Q, Ridgway LD et al (2003) Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 13:399-404
18. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288
19. Jobin C, Sartor RB (2000) The IkB/NF-B system. a key determinant of mucosa inflammation and protection. Am J Physiol Cell Physiol 278:C451-C562
20. Senftleben U, Cao Y, Xiao G et al (2001) Activation by IKK of a second, evolutionary conserved, NF-κB signaling pathway. Science 293:1495-1499
21. Romieu-Mourez R, Landesman-Bollag E, Seldin DC et al (2001) Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res 61:3810-3818
22. Mathas S, Lietz A, Janz M et al (2003) Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102:1028-1034
23. Bava SV, Puliappadamba VT, Deepti A et al (2005) Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280:6301-6308
24. Li Y, Ahmed F, Ali S et al (2005) Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934-6942
25. Mabuchi S, Ohmichi M, Nishio Y et al (2004) Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279:23477-23485
26. Patel NM, Nozaki S, Shortle NH et al (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IB super-repressor and parthenoide. Oncogene 19:4159-4169
27. Kim DW, Sovak MA, Zanieski G et al (2000) Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21:871-879
28. Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404:892-897
29. Nozaki S, Sledge GW Jr, Nakshatri H (2001) Repression of GADD153/CHOP by NF-kappaB: A possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 20:2178-2185
30. Costa C, Soares R, Reis-Filho JS et al (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429-434
31. Zhang S, Lin ZN, Yang CF et al (2004) Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 25:2191-2199
32. Weldon CB, Burow ME, Rolfe KW et al (2001) NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 130:143-150
33. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239-252
34. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37-40
35. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912
36. Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101:4667-4679
37. Bohmann D, Bos TJ, Admon A et al (1987) Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238:1386-1392
38. Sánchez I, Hughes RT, Mayer BJ et al (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-798
39. Lin W, Kao HW, Robinson D et al (2000) Tyrosine kinases and gastric cancer. Oncogene 19:5680-5689
40. Wu CW, Li AF, Chi CW et al (2000) Human gastric cancer kinase profile and prognostic significance of MKK4 kinase. Am J Pathol 156:2007-2015
41. Sánchez-Pérez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540
42. Stadheim TA, Kucera GL (2002) c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone-and anisomycin-induced apoptosis in HL-60 cells. Leuk Res 26:55-65
43. Teng DH, Perry WL 3rd, Hogan JK et al (1997) Human mitogen-activated protein kinase 4 as a candidate tumor suppressor. Cancer Res 57:4177-4182
44. Su GH, Song JJ, Repasky EA et al (2002) Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat 19:81
45. Wada T, Joza N, Cheng HY et al (2004) MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol 6:215-226
46. Sánchez-Pérez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540
47. Sánchez-Pérez I, Perona R (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 453:151-158
48. Sánchez-Pérez I, Martínez-Gomariz M, Williams D et al (2000) CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19:5142-5152
49. Sánchez-Pérez I, Benitah SA, Martínez-Gomariz M et al (2002) Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell 13:2933-2945
50. Wang HY, Cheng Z, Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191:229-237
51. Denkert C, Schmitt WD, Berger S et al (2002) Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 102:507-51
52. Chattopadhyay S, Machado-Pinilla R, Manguan-García C, et al (2006) MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small cell lung cancer 25:3335-3345